Clinical Trial Search

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants

Primary: Overall Response Rate — 9 percent

Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs

Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients

Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants

Primary: Progression-free Survival at 6 Months. — 39; 6 Participants

Primary: Response Rate — 22 percentage of participants

Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants

Primary: 6-month Progression-free Survival — 88.8 percentage of participants

Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients

Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants

Primary: 1-year Overall Survival (OS) — 80 percentage of participants

Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Response Rate

Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants

Primary: ORR — 0; 0; 0; 0 percentage of patients

Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants

Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants

Primary: Maximum Tolerated Dose of Everolimus for Participants With Recurrent Malignant Gliomas — 5 mg

Primary: 6-Month Progression Free Survival — 0 percentage of participants

Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants

Primary: Number of Participants With Dose-limiting Toxicities Due to Romidepsin Graded According to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I) — 0 participants

Primary: Phase I: Number of Patients With Dose-limiting Toxicity (DLT) — 2; 2; 2 Participants

Primary: 6 Months Progression-free Survival — 3 percent

Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L

Primary: Response Rate (Complete and Partial Response) — 7 Participants